


Claims

Claims 1-14. **(canceled)**

15. **(previously presented)** A polypharmacophore represented by formula **(II)**:



(II)

wherein:

R₁ is -CO₂R₄ or -CON(R₄)₂;

R₂ represents independently for each occurrence H, F, Cl, Br, or I;

R₃ represents independently for each occurrence H, F, Cl, Br, or I;

R₄ represents independently for each occurrence H or alkyl; and

the stereochemical configuration of the carbon-carbon double bond is *Z*, *E*, or a mixture of *Z* and *E*.

Claims 16-54. **(canceled)**


55. **(previously presented)** The polypharmacophore of claim 15, wherein R₂ is F.

56. **(previously presented)** The polypharmacophore of claim 15, wherein R₂ is F and R₃ is H.

57. **(previously presented)** The polypharmacophore of claim 15, wherein R₁ is CO₂R₄.


58. **(previously presented)** The polypharmacophore of claim 15, wherein R₁ is CO₂R₄ and R₄ is H.


59. **(previously presented)** The polypharmacophore selected from group consisting of:



60. **(previously presented)** A pharmaceutical composition, comprising:
a polypharmacophore of claim 15, 55, 56, 57, 58 or 59, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.

61. **(new)** A polypharmacophore selected from group consisting of:





62. (new) A pharmaceutical composition, comprising: a polypharmacophore of claim 61, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.